Ozempic Cost in the US (2026)

The short answer on Ozempic’s price

There is no single “price” for Ozempic, and the spread is enormous. The same pen can cost one person $25 a month and another person more than $1,000, depending entirely on their insurance and their diagnosis. The sticker (list) price sits at roughly $936 a month, but that number mostly matters as a starting point for negotiation between manufacturers and insurers — very few patients pay it directly.

What actually decides your cost is a short list of questions: Do you have insurance, and is it commercial or government? Does your plan cover Ozempic? And, critically, do you have a type 2 diabetes diagnosis? Because Ozempic is approved for diabetes — not weight loss — that last question often matters more than the others.

List price vs what people actually pay

Ozempic is sold as a once-weekly injectable pen, with each pen supplying a month at a given strength. All pen strengths are priced almost identically at list, so a higher dose doesn’t usually mean a higher sticker price (the 2 mg pen is an exception on the self-pay program). Here’s the 2026 landscape across the common ways people pay:

The takeaway is that the retail cash price is almost never the price worth paying. Below it sit several legitimate, well-traveled routes that bring the cost down substantially — and which one fits you is the real question.

NovoCare self-pay: the cash route

If you don’t have insurance, or your plan won’t cover Ozempic, Novo Nordisk’s own pharmacy program (NovoCare) is usually the cleanest cash option. Through it, the 0.25 mg, 0.5 mg, and 1 mg pens are priced at $349 a month, and the 2 mg pen at $499 a month. Those are flat prices that undercut typical retail cash significantly.

There’s also an introductory rate: patients new to the program can pay $199 a month for their first two starter-dose fills (0.25 mg and 0.5 mg), available through June 30, 2026, before stepping up to the standard self-pay price. Promotional windows like this change, so treat the dates as current-as-of this article’s update and confirm directly before relying on them.

Note: NovoCare self-pay and the savings card are mutually exclusive — self-pay is for the uninsured, the card is for the commercially insured. You pick the lane that matches your coverage.

The $25 savings card (and who it excludes)

The NovoCare savings card is the single most powerful tool for people who already have commercial insurance that covers Ozempic. Eligible patients can pay as little as $25 per fill, with a cap on how much the card pays each fill — roughly up to $100 in savings for a one-month supply, $200 for two months, and $300 for three months, and it can be used for up to 48 months from activation. There’s no income limit; the requirement is the right kind of insurance plus an on-label diabetes use.

The exclusions are strict and trip a lot of people up. The card cannot be used by anyone on a government plan — Medicare, Medicaid, TRICARE, VA, DoD, or Medigap — and that’s true even if you offer to pay cash out of pocket. It also can’t be stacked with a discount card like GoodRx on the same fill. Your real cost with the card is your normal copay minus the card’s contribution, down to the $25 floor: if your copay is $35 you’d pay $25, but if your plan doesn’t cover Ozempic at all, the $25 path simply doesn’t exist for you.

Patient assistance for uninsured or low-income patients

Separate from both of the above, Novo Nordisk runs a Patient Assistance Program (PAP) for people who are uninsured and meet income limits — generally a household income at or below 200% of the Federal Poverty Level (roughly $31,920 for one person or $43,280 for a household of two in 2026). Qualifying patients may receive their medication at no cost. PAP enrollment is more involved than activating a card, but for people who genuinely can’t afford any of the cash prices, it’s the route worth pursuing first.

Medicare and Ozempic

Medicare is its own world, and the details here are covered more fully on our insurance page — but the basics matter for cost. Medicare Part D plans generally do cover Ozempic when it’s prescribed for type 2 diabetes; what you pay depends on your specific plan’s tier and phase. The important 2026 backstop is the Inflation Reduction Act’s out-of-pocket cap, which limits a Part D enrollee’s total covered-drug spending to $2,100 for the year. That cap can meaningfully change the math for someone taking an expensive drug like Ozempic.

Two changes are on the horizon rather than fully in effect for 2026. First, semaglutide (the molecule in Ozempic, Wegovy, and Rybelsus) was selected in Medicare’s second round of drug-price negotiation, with a negotiated maximum fair price of $274 for a month’s supply — but that price takes effect January 1, 2027, not 2026. Second, a separately announced arrangement would make Ozempic and Wegovy available to Part D plans at a lower price with a $50 monthly copay and broader obesity coverage starting around mid-2026, though the operational timing has not been finalized. For Medicare patients today, the practical reality is: Part D covers it for diabetes, the savings card does not apply, and the annual cap is the safety net.

Why “Ozempic for weight loss” usually costs more

This is the part that surprises people. Ozempic and Wegovy are the same drug — semaglutide — but they are different brands approved for different things. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. Insurers track that distinction closely.

If you have diabetes, Ozempic is often the cheaper, better-covered path, and the $25 savings card is built for exactly your situation. If you’re seeking the medication purely for weight loss, prescribing Ozempic is off-label, and most plans won’t cover it for that purpose — which usually pushes you toward the NovoCare self-pay price or the full cash price. For weight loss specifically, the on-label brand (Wegovy) has its own coverage and cost structure, and that’s the better comparison to run. In short: your diagnosis, not just your insurance, is a price variable.

GoodRx, pharmacy shopping, and discount cards

For people paying cash who don’t qualify for or want the manufacturer programs, third-party discount tools like GoodRx typically bring Ozempic down to roughly $700–$900 a month — better than full retail, but generally not as low as NovoCare self-pay. Prices also vary by pharmacy, sometimes by a few hundred dollars for the identical pen, so it’s worth checking a couple of nearby pharmacies before filling. Remember that a discount card can’t be combined with the manufacturer savings card on the same prescription, so you’re choosing between them, not adding them together.

There is no generic semaglutide as of 2026, so none of these routes are a “generic discount” — they’re all different ways of paying for the same brand-name pen.

How Ozempic’s cost compares

Because Ozempic, Wegovy, and Mounjaro/Zepbound get lumped together in conversation, it’s easy to assume their prices are interchangeable. They aren’t, and the differences come down to brand, indication, and which manufacturer programs apply. We keep the head-to-head numbers on dedicated pages rather than duplicating them here — see our companion guides on semaglutide cost overall, Wegovy cost, and the direct-to-consumer pricing landscape — and the clinical “which is better” question lives on the comparison pages.

Bottom line: which path fits you

• Commercial insurance + type 2 diabetes: the savings card is almost certainly your cheapest route — aim for about $25 a month.
• Uninsured, paying cash: start with NovoCare self-pay ($349, or $199 to start as a new patient through mid-2026) before settling for retail or GoodRx.
• Uninsured and low income: check the Patient Assistance Program first — it may cost you nothing.
• On Medicare: your Part D coverage and the 2026 out-of-pocket cap do the heavy lifting; the savings card is off the table.
• Taking it for weight loss, not diabetes: expect coverage to be the sticking point, and compare against Wegovy rather than assuming Ozempic will be covered.

Prices and programs in this space change frequently — the figures here are current as of this article’s update and should be confirmed with your pharmacy, your plan, or NovoCare before you make a decision.